Infliximab

Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer

Retrieved on: 
Tuesday, February 13, 2024

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
  • Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
  • Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period.
  • Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis.

Johnson & Johnson Reports Q4 and Full-Year 2023 Results

Retrieved on: 
Tuesday, January 23, 2024

Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.

Key Points: 
  • Adjusted operational sales* reflected below excludes the net impact of acquisitions and divestitures and translational currency.
  • Innovative Medicine worldwide operational sales, excluding the COVID-19 Vaccine, grew 7.2%*.
  • Notable New Announcements in the Quarter:
    The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.
  • Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.

Celltrion presents strategic vision and growth plan at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 11, 2024

Celltrion's Chairman Jung-Jin Seo and CEO Jin-Seok Seo discussed the company's strategic priorities and progress, including the company's vision to move beyond biosimilars through the 2024 launch of ZYMFENTRA™ in the U.S. and expansion into digital healthcare.

Key Points: 
  • Celltrion's Chairman Jung-Jin Seo and CEO Jin-Seok Seo discussed the company's strategic priorities and progress, including the company's vision to move beyond biosimilars through the 2024 launch of ZYMFENTRA™ in the U.S. and expansion into digital healthcare.
  • He also shared insights and trends on the biosimilar industry and how the market landscape is impacting Celltrion's strategy.
  • Jin-Seok Seo said, ''Celltrion has the potential to grow its revenue by at least fivefold in 2030, once our 22-drug portfolio is commercialized.
  • Celltrion remains committed to pursuing its goal in promoting the health and well-being of patients."

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

Retrieved on: 
Monday, November 13, 2023

These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.

Key Points: 
  • These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.
  • However, the influx of innovative agents suggests that upcoming changes are poised to be more substantial and transformative.
  • This extension enjoys the highest pre-launch familiarity and generates significantly higher interest in gaining approval.
  • Although prescribers display significant enthusiasm for Entyvio SC, its anticipated impact on the broader market is projected to be modest.

Inflectra Announces Partnership with Trustify Technology

Retrieved on: 
Wednesday, December 6, 2023

WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Inflectra, a global market leader in IT Software Lifecycle Management solutions, announced its partnership with Trustify Technology.

Key Points: 
  • WASHINGTON, Dec. 6, 2023 /PRNewswire/ -- Inflectra, a global market leader in IT Software Lifecycle Management solutions, announced its partnership with Trustify Technology.
  • Trustify Technology, headquartered in Ho Chi Min City, Vietnam, services customers around the globe with Agile Software Development, QA Testing, Big Data, Machine Learning, and AI.
  • Trustify Technology benefits from Inflectra's established market influence and a suite of comprehensive lifecycle management solutions.
  • CEO and Founder of Inflectra, Adam Sandman, shares: "We are excited to forge a partnership with Trustify Technology, with their deep development experience and market knowledge of Vietnam.

Kexing Biopharm Attended CPHI Worldwide 2023

Retrieved on: 
Tuesday, November 7, 2023

SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held in Barcelona, Spain.

Key Points: 
  • SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held in Barcelona, Spain.
  • Although Kexing Biopharm specially booked a large booth including independent conference rooms for this exhibition, the seats were still packed with customers who came in an endless stream, and the scene was extremely popular.
  • Many overseas customers expressed great interest in several high-end drugs shown by Kexing Biopharm, and actively explored joint development of overseas business with the company.
  • The participating team of Kexing Biopharm exchanged experiences and discussed with industry leaders, aiming to explore the future development of the industry.

Kexing Biopharm Attended CPHI Worldwide 2023

Retrieved on: 
Tuesday, November 7, 2023

SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held in Barcelona, Spain.

Key Points: 
  • SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held in Barcelona, Spain.
  • Although Kexing Biopharm specially booked a large booth including independent conference rooms for this exhibition, the seats were still packed with customers who came in an endless stream, and the scene was extremely popular.
  • Many overseas customers expressed great interest in several high-end drugs shown by Kexing Biopharm, and actively explored joint development of overseas business with the company.
  • The participating team of Kexing Biopharm exchanged experiences and discussed with industry leaders, aiming to explore the future development of the industry.

Montai Health Appoints Christian Antoni, M.D., Ph.D., as Company’s First Chief Medical Officer

Retrieved on: 
Tuesday, October 24, 2023

CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Montai Health, a company solving the chronic disease challenge by connecting complex biology to untapped human chemistry with AI to improve patients’ lives, today announced the appointment of Christian Antoni, M.D., Ph.D., as Chief Medical Officer. Dr. Antoni will lead the company’s development of scalable and efficient clinical operating capabilities to translate into the clinic a rapidly expanding pipeline of potential first-in-class oral therapies with an initial focus on chronic inflammatory and autoimmune diseases.

Key Points: 
  • Montai Health Appoints Christian Antoni, M.D., Ph.D., as Chief Medical Officer
    A rheumatologist by training, Dr. Antoni most recently was the Chief Development Officer at EQRx.
  • Montai’s CONECTA™ Platform is enabling breakthroughs in predictably developing first-in-class small-molecule medicines with potential for long-term safety and earlier intervention.
  • Changing this model has the potential to transform patient outcomes at scale.”
    Dr. Antoni completed his medical training and residency in internal medicine and rheumatology at Friedrich-Alexander University, Germany.
  • Dr. Antoni joins an industry-leading scientific and drug development team with decades of collective experience bringing novel, impactful medicines to the clinic across multiple therapeutic areas, including:

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Retrieved on: 
Monday, October 23, 2023

Based on the results of the LIBERTY UC and LIBERTY CD studies, ZYMFENTRA demonstrated superiority in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) compared to placebo as maintenance therapy after induction therapy of intravenous formulation of infliximab in patients with UC and CD, over a 54-week study period.

Key Points: 
  • Based on the results of the LIBERTY UC and LIBERTY CD studies, ZYMFENTRA demonstrated superiority in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) compared to placebo as maintenance therapy after induction therapy of intravenous formulation of infliximab in patients with UC and CD, over a 54-week study period.
  • The overall safety profile of ZYMFENTRA was similar to that of placebo during maintenance period in both studies with no new safety signals seen.2,3
    “There remains an unmet need for patients who suffer from the day-to-day burden of living with moderately to severely active Crohn’s disease and ulcerative colitis,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA.
  • “As someone dedicated to improving the lives of patients with IBD, I am excited to see data supporting the efficacy and safety of a new formulation offering convenience and improved access to a well-known and proven drug,” said Dr. Andres Yarur of Cedars-Sinai Medical Center.
  • ZYMFENTRA will be under patent protection by 2037 for its dosage form and route of administration by 2040.

ProciseDx Expands Intellectual Property Portfolio with Purchase of Two US Therapeutic Drug Monitoring Patents

Retrieved on: 
Wednesday, October 18, 2023

SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing global patent portfolio.

Key Points: 
  • SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has purchased two US patents in therapeutic drug monitoring (TDM) of biologic drugs to supplement its existing global patent portfolio.
  • 11,119,096 "Universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug antibodies in samples" and US Patent No.
  • "We believe these patents as well as our existing intellectual property forms a solid foundation for our path forward in expanding our reach in therapeutic drug monitoring of biological drugs," said Larry Mimms, PhD, CEO of ProciseDx.
  • ProciseDx received FDA clearance for the ProciseDx analyzer and first immunoassay for C-Reactive protein (CRP) in November, 2022.